Navigation Links
FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
Date:6/23/2008

Companies confirm the start of TRILOGY ACS clinical trial to study

Prasugrel against Clopidogrel in medically managed ACS patients

TOKYO and INDIANAPOLIS, June 23 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited, (TSE:4568) and Eli Lilly and Company (NYSE: LLY) said that the U.S. Food and Drug Administration (FDA) has extended the review period for the prasugrel new drug application (NDA) based on supplemental information provided during the review period. This three month extension allows the FDA time to complete its review. The prasugrel NDA was granted priority review by the FDA in February 2008. The new FDA action date for prasugrel is September 26, 2008. The proposed indication for prasugrel is for the treatment of patients with acute coronary syndromes (ACS) being managed with an artery- opening procedure known as percutaneous coronary intervention (PCI).

Daiichi Sankyo and Lilly also confirm the start this month, as planned, of the TRILOGY ACS trial, a large Phase III clinical trial to compare the effects of prasugrel against clopidogrel (Plavix(R)/Iscover(R)) in medically managed ACS patients.

"We remain confident in our prasugrel submission package," said Jennifer Stotka, M.D., vice president for Global Regulatory Affairs at Lilly. "The TRITON trial encompassed a large amount of data from over 13,000 patients. We will continue to work closely with the FDA throughout the review process and continue discussions to determine if any requirements under the new FDA Amendment Act (FDAAA) legislation will apply."

"The initiation of the TRILOGY ACS trial demonstrates our continued commitment to investigate prasugrel as a potential therapy for ACS patients who are medically managed," said John A
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
3. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. GSK Update on FDA Review of Promacta(R) (Eltrombopag)
8. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
9. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
10. Got Fat?: Plastic Surgeons Review Fat-Melting and Fat-Grafting Procedures
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 In a recent study ... backflow of the Eldor spinal needle 25G, 103 mm ... pencil point spinal needles of the same gauge and ... anesthesia is an excellent type of regional anesthesia for ... etc. It is estimated that 100 million ...
(Date:9/30/2014)... September 2014 ... Acutus Medical, Inc. ... 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in Echtzeit zur ... komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern führen bzw. ... zusätzlichen Finanzierung über 26,2 Mio. USD ...
(Date:9/30/2014)... Sept. 30, 2014  The orthopedic specialists at Midwest ... 6 orthopedic group by US News & World Report, ... series of free, public seminars to discuss partial and ... world come to see the knee physicians at Midwest ... available at Munster Specialty Surgery Center. ...
Breaking Medicine Technology:Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2
... 20 In an effort to ... supply chain, Siemens Healthcare Diagnostics (Siemens) has published product data ... U.S. product line into the GHX Health ConneXion(SM) data pool. ... GS1,s Global Data Synchronization Network (GDSN®) that is focused solely ...
... Kinetic Systems, Inc., a leading global provider of process ... clients, announced today the appointment of Peter M. Maris ... to its Board of Directors. He will also continue ... Mr. Maris has been with Kinetics for more than ...
Cached Medicine Technology:Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool 2Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool 3Kinetic Systems Appoints Peter M. Maris President & Chief Executive Officer 2
(Date:9/30/2014)... 30, 2014 This two-day, advanced ... vestibular sequellae that may arise following a concussion ... concussions can be varied, from sports related injuries, car ... sustained by the thousands of returning soldiers from war ... blast and blunt traumas can result in similar injuries, ...
(Date:9/30/2014)... Amy Norton ... News) -- Long-acting contraceptive devices should be the first ... from the American Academy of Pediatrics state. Although ... pills, two other forms of contraception -- intrauterine devices ... according to the academy. And they should be ...
(Date:9/30/2014)... HealthDay Reporter , MONDAY, Sept. ... broad-spectrum antibiotics before the age of 2 may face ... new research suggests. Broad-spectrum antibiotics target a larger ... study. "It is a reason to think about ... picking," said lead researcher Dr. Charles Bailey, attending physician ...
(Date:9/30/2014)... Thompson HealthDay Reporter MONDAY, ... receive medical implants -- artificial valves, hip replacements, surgical mesh ... tested before or after their approval by the U.S. Food ... -- conducted by prominent nonprofit groups and published online Sept. ... blame for inadequate medical device testing on lax oversight by ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... provider in the nation, today announced that Adam ... Healthcare’s anesthesiology division, will present at the Society ... SHSMD Connections 2014 . The conference will ... , SHSMD Connections is a four-day conference that ...
Breaking Medicine News(10 mins):Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 3Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 2Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 3
... has announced,the appointment of Florence L. DiBenedetto as senior ... January 5, 2009, succeeding longtime,General Counsel Gary Loveridge who ... Formerly senior partner of the Sacramento-based law firm Hunter ... decades, DiBenedetto,served for more than 10 years as the ...
... Progressive Lenses and Transitions® Lenses to Produce Optimal Visual Experience ... ... Two of the most distinguished names in the optical industry are ... ,Carl Zeiss Vision, a leader for 160 years in precision optics, ...
... Dec. 17 Hologic, Inc. (Nasdaq: HOLX ), ... imaging systems and surgical products dedicated to serving the healthcare ... quarter fiscal 2009 operating results on Monday, February 2, 2009 ... host a conference call on Monday, February 2, 2009 at ...
... eggs to fertility clinics reported satisfaction with the process, ... 20 percent reported lasting psychological effects, according to the ... , The research by scientists at the University of ... 20 states and is the largest study to explore ...
... 1 Million Prescriptions , , ... wholly owned subsidiary of the Cystic Fibrosis Foundation, today announced ... cystic fibrosis (CF) community nationwide. , , ... patient, one prescription and a mission to improve access to ...
... to Meet Joint Commission Compliance through Patient Engagement , ... In an effort to improve patient safety and standards ... Patient Care (IPC) solutions, is enabling King,s Daughters Medical Center ... Patient Safety Goal (NPSG) 16 through GetWellNetwork,s interactive PatientLife ...
Cached Medicine News:Health News:Sutter Health Welcomes New General Counsel 2Health News:Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers 2Health News:Hologic, Inc. to Release First Quarter Fiscal 2009 Operating Results on Monday, February 2, 2009 2Health News:Most women report satisfaction with egg donation; some claim problems 2Health News:Most women report satisfaction with egg donation; some claim problems 3Health News:Cystic Fibrosis Services Pharmacy Celebrates 20th Anniversary 2Health News:King's Daughters Medical Center Leverages Unique Bedside Interactive Technology to Meet Requirements of Patient Safety Goal 16 2Health News:King's Daughters Medical Center Leverages Unique Bedside Interactive Technology to Meet Requirements of Patient Safety Goal 16 3
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Inquire...
Inquire...
Medicine Products: